Lectra And 2 Other High Growth Tech Stocks In France

As the European Central Bank's recent rate cuts have spurred optimism for further monetary easing, France's CAC 40 Index has seen a modest rise, reflecting broader positive sentiment across major European markets. In this environment of potential economic support and easing inflationary pressures, high-growth tech stocks in France like Lectra are gaining attention for their innovative capabilities and strong market positioning.

Top 10 High Growth Tech Companies In France

Name	Revenue Growth	Earnings Growth	Growth Rating
Icape Holding	17.24%	33.91%	★★★★★☆
Archos	24.36%	78.41%	★★★★★☆
Valneva	22.84%	18.29%	★★★★★☆
Valbiotis	43.33%	42.78%	★★★★★☆
beaconsmind	25.00%	81.09%	★★★★★★
Oncodesign Société Anonyme	14.68%	101.18%	★★★★★☆
Munic	42.94%	174.09%	★★★★★☆
VusionGroup	28.35%	81.72%	★★★★★★
Adocia	70.20%	63.97%	★★★★★☆
Pherecydes Pharma Société anonyme	63.30%	78.85%	★★★★★☆

Click here to see the full list of 39 stocks from our Euronext Paris High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Lectra (ENXTPA:LSS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Lectra SA offers industrial intelligence solutions for the fashion, automotive, and furniture sectors across Northern Europe, Southern Europe, the Americas, and the Asia Pacific with a market cap of €988.65 million.

Operations: Lectra SA generates revenue from providing industrial intelligence solutions, with significant contributions from the Americas (€172.65 million) and Asia-Pacific (€118.54 million).

Despite a challenging year with earnings contracting by 16.8%, Lectra's resilience is evident in its revenue growth, which at 10.4% annually, outpaces the French market's average of 5.6%. This performance underscores the company's robust position in tech innovation, particularly in software solutions for fashion and automotive industries. Notably, Lectra invests significantly in R&D to stay ahead, with expenses marking a substantial portion of their revenue stream to fuel future advancements. Looking ahead, the company is poised for a striking rebound with earnings expected to surge by 29.3% annually over the next three years—demonstrating potential for substantial growth amidst evolving industry demands and increasing digital adoption across its client sectors.

• Dive into the specifics of Lectra here with our thorough health report.

• Learn about Lectra's historical performance.

OVH Groupe (ENXTPA:OVH)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: OVH Groupe S.A. offers a range of cloud services including public and private cloud, shared hosting, and dedicated server solutions globally, with a market cap of approximately €1.49 billion.

Operations: The company generates revenue primarily from its Private Cloud segment, contributing €589.61 million, followed by Web Cloud & Other at €185.43 million and Public Cloud at €169.01 million.

OVH Groupe's recent engagement at the 2024 OCP Global Summit highlights its active role in global tech discussions, a positive signal for stakeholders. Despite current unprofitability, the company is on a path to profitability with an impressive expected earnings growth of 101.4% annually. This contrasts sharply with its modest revenue growth forecast of 9.7% per year, which still outstrips the French market average of 5.6%. OVH invests robustly in R&D, aligning expenses significantly with revenue to innovate and capture market trends effectively—essential for sustaining long-term growth in a competitive landscape marked by rapid technological advancements and shifting industry dynamics.

• Click to explore a detailed breakdown of our findings in OVH Groupe's health report.

• Evaluate OVH Groupe's historical performance by accessing our past performance report.

Valneva (ENXTPA:VLA)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for infectious diseases with unmet needs, with a market capitalization of approximately €435.15 million.

Operations: Valneva SE generates revenue primarily through the development and commercialization of prophylactic vaccines, amounting to approximately €156.47 million.

Valneva, amid a flurry of strategic moves and regulatory milestones, is carving a niche in the high-growth biotech sector by focusing on vaccines for underserved diseases. The company's recent FDA Fast Track designation for its Shigella vaccine underscores its commitment to addressing global health challenges, with R&D expenses aligning closely with these innovative pursuits. Notably, Valneva's revenue is expected to surge by 22.8% annually, outpacing the broader French market's growth. Furthermore, the firm has projected an 18.3% annual increase in earnings as it advances its pipeline including potential market expansions and new launches like the IXCHIQ vaccine for adolescents. These strategic initiatives are supported by substantial investments in R&D to fuel future growth and enhance global health outcomes.

• Take a closer look at Valneva's potential here in our health report.

• Gain insights into Valneva's past trends and performance with our Past report.

Key Takeaways

• Take a closer look at our Euronext Paris High Growth Tech and AI Stocks list of 39 companies by clicking here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com